Call for Feedback Deadline: November 9, 2015 at 5:00 p.m. ET via email to email@example.com.
CADTH is inviting stakeholder comments and feedback on the proposed framework to align drug expert committee recommendations to be used in both the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs.
Background and Context
At the Stakeholder Engagement Session held on February 5, 2015, CADTH announced its intent to create a single recommendation framework that is applied by its drug expert committees (the CADTH Canadian Drug Expert Committee [CDEC] and the CADTH pCODR Expert Review Committee [pERC]).
Table 1 summarizes the current CDR and pCODR categories of recommendation options.
Table 1: Current Recommendation Categories
|CDR Recommendation Categories||pCODR Recommendation Categories|
|There are four recommendation categories:
||There are three recommendation categories:
As part of the ongoing process to align the two programs, CADTH and the participating jurisdictions have agreed that the following three recommendation categories and terminology will be adopted for use in both CDR and pCODR :
- Reimburse with clinical criteria and/or conditions
- Do not reimburse
In view of these changes, CADTH is drafting a revised recommendation framework for CDR and pCODR based on the three new categories. This proposed framework is intended to be incorporated into the existing deliberative frameworks and processes to support the CADTH drug expert committees in making recommendations to the participating jurisdictions to guide their reimbursement decisions.
If you have any questions about the feedback process, please email us at firstname.lastname@example.org. We thank you in advance for your interest.